recent publications

• academic article

  • Robinson, K., Mayer, E. L., Miller, D. P., Green, R., Vanlente, F., Gupta, A., Kottkemarchant, K., Savon, S. R., Selhub, J., Nissen, S. E., Kutner, M., Topol, E. J. Hyperhomocysteinemia and low pyridoxal-phosphate - common and independent reversible risk-factors for coronary-artery disease Circulation  1995 92:2825-2830  PMID:7586248
  • Harrington, R. A., Kleiman, N. S., Kottkemarchant, K., Lincoff, A. M., Tcheng, J. E., Sigmon, K. N., Joseph, D., Rios, G., Trainor, K., Rose, D., Greenberg, C. S., Kitt, M. M., et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein iib/iiia inhibitor during percutaneous coronary intervention American Journal of Cardiology  1995 76:1222-1227  DOI:10.1016/s0002-9149(99)80345-2  PMID:7503000
  • Tcheng, J. E., Harrington, R. A., Kottkemarchant, K., Kleiman, N. S., Ellis, S. G., Kereiakes, D. J., Mick, M. J., Navetta, F. I., Smith, J. E., Worley, S. J., Miller, J. A., Joseph, D. M., et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein iib/iiia blocker integrelin in elective coronary intervention Circulation  1995 91:2151-2157  PMID:7697843
  • Nicolini, F. A., Lee, P., Rios, G., Kottkemarchant, K., Topol, E. J. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low-doses markedly improves thrombolysis Circulation  1994 89:1802-1809  PMID:8149546